Verisante Technology Inc., a medical device company, engages in commercializing skin cancer detection systems. The company's products comprise Verisante Aura, which helps in the detection of various forms of skin cancer, including basal cell and squamous cell carcinoma, and melanoma; and Verisante Core for the detection of lung, cervical, gastrointestinal, and colo-rectal cancers. It also owns all the rights to the ClearVu and ClearVu Elite endoscopy systems for the detection of lung cancer. Verisante Technology has a licensing agreement with the BC Cancer Agency for the manufacture, distribution, and sale of products based on patented skin cancer detection technology. The company was formerly known as T-Ray Science Inc. and changed its name to Verisante Technology Inc. in January 2011. Verisante Technology Inc. was founded in 2006 and is based in Richmond, Canada.
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-604-6050507
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Verisante Technology (CVE:VRS) Frequently Asked Questions
What is Verisante Technology's stock symbol?
Verisante Technology trades on the Canadian Venture Exchange (CVE) under the ticker symbol "VRS."
Has Verisante Technology been receiving favorable news coverage?
News articles about VRS stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Verisante Technology earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Verisante Technology.
Who are some of Verisante Technology's key competitors?
Some companies that are related to Verisante Technology include Smith & Nephew (SN), Corindus Vascular Robotics (CVRS), Consort Medical (CSRT), Ekf Diagnostics (EKF), Immunodiagnostic Systems (IDH), Theralase Technologies (TLT), Intelligent Ultrasound Group (MED), LiDCO Group (LID), Deltex Medical Group (DEMG), Zecotek Photonics (ZMS), InspireMD (NSPR), Lucid (LCDX) and MCP Income Opp Trust Ordinary Units FP (MOT).
Who are Verisante Technology's key executives?
Verisante Technology's management team includes the folowing people:
- Mr. Thomas A. Braun BA, J.D., LLM, Chief Exec. Officer, Pres and Director (Age 50)
- Ms. Anna Trinh B.Comm LLB, Chief Financial Officer, Corp. Counsel and Sec. (Age 44)
- Mr. Rizah Bahic, Exec. Officer
How do I buy shares of Verisante Technology?
Shares of VRS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Verisante Technology's official website?
How can I contact Verisante Technology?
Verisante Technology's mailing address is 2309 41st Ave W Suite 306, VANCOUVER, BC V6M 2A3, Canada. The company can be reached via phone at +1-604-6050507.
MarketBeat Community Rating for Verisante Technology (CVE VRS)
MarketBeat's community ratings are surveys of what our community members think about Verisante Technology and other stocks. Vote "Outperform" if you believe VRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
